Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. (November 2017)

• Record Type: Journal Article
• Authors: Iijima, Toshie; Kato, Kanako; Jojima, Teruo; Tomotsune, Takanori; Fukushima, Maiko; Suzuki, Kunihiro; Aso, Yoshimasa
• Is Part Of: Diabetes research and clinical practice. Volume 133(2017)
• Page Start: 10
• Page End: 12
• Publication Date: 2017-11
• Subjects: Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2017.07.036
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Programed cell death protein-1 (PD-1) is an inhibitory receptor expressed by T cells that downregulates the activation and proliferation of these cells to maintain peripheral self-tolerance. Recent studies reported some cases of new-onset type 1 diabetes (T1D) under anti-PD1 or PDL-1 antibodies. We demonstrated that circulating both CD4+PD-1+ and CD8+PD-1+ T cells were profoundly reduced at the onset of fulminant T1D and were restored by treatment in two patients with fulminant T1D.